Merck reports trial data as MarketBeat cites USD 146.36 for Merck stock

Published on 10/06/2026 at 17:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Tulisokibart reached 72.00 percent HiSCR50 at high dose. Merck stock was last at EUR 124.78 on October 6, 2026 versus EUR 124.42.

Editorial photograph of a large curved widescreen trading monitor displaying pharmaceutical sector data. Panels labeled PHARMA, ONCOLOGY, VACCINES, NYSE show upward-trending line charts and candlestick data in green and white on a dark charcoal background — Merck US58933Y1055 NYSE-Editorial: Handelsmonitor zeigt Pharma, Oncology, Vaccines und NYSE mit steigenden Sektor-Charts, Illustration mit AI erstellt.

Merck & Co. (ISIN US58933Y1055) was last at a substitute Xetra price of EUR 124.78 on October 6, 2026, versus EUR 124.42 previously. The company reported positive Phase 2b tulisokibart data on September 30, while MarketBeat cited an average one-year price target of USD 146.36 on October 6.

Tulisokibart clears Phase 2b test

According to Merck on September 30, 2026, 72.00 percent of patients receiving the high-dose regimen achieved HiSCR50 at week 16, compared with 35.00 percent for placebo. The medium-dose group reached 64.00 percent, giving Merck two active regimens above the placebo result.

The same release reported HiSCR75 responses of 41.00 percent for high-dose patients and 15.00 percent for placebo. Adverse events occurred in 42.90 percent of the high-dose group and 40.90 percent of placebo patients, putting efficacy and tolerability side by side in the early-stage evidence.

Revenue beat supports the pipeline

Merck's second-quarter 2026 revenue was USD 16.61 billion, compared with USD 16.37 billion expected, according to MarketBeat. Revenue increased 5.10 percent year over year, although the standardized financial data show a net loss of USD 1.34 billion for the quarter.

For the stock, the key distinction is between commercial momentum and pipeline execution. Tulisokibart's 37.00-point high-dose advantage over placebo in HiSCR50 gives investors a measurable clinical signal, while the next earnings call on October 29 will provide the next scheduled operating update.

Next results arrive October 29

Merck said on October 1, 2026, that it will hold its third-quarter 2026 sales and earnings conference call on October 29 at 9:00 a.m. ET. The event matters because the second-quarter revenue comparison was positive, while the company is also expanding its late-stage pipeline across oncology and immunology.

Merck was last at EUR 124.78 on Xetra on October 6, 2026 at 4:54 p.m. CEST, versus the previous close of EUR 124.42, a plus 0.29 percent change. The primary listing is on the NYSE, where the finance quote showed USD 141.73 and a 52-week range of USD 82.01 to USD 156.92 on October 6, 2026.